SCHEMBL30145306

SCHEMBL30145306

CCNC(=O)Nc1ccc(-c2ccc(OC)cc2Cl)n2cc(CC(=O)O)nc12

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ABL1 P00519 3/20 0.37
▸ KMT2A Q03164 4/20 0.37
▸ CYP1A2 P05177 1/20 0.37
▸ CYP3A4 P08684 1/20 0.37
▸ CYP2D6 P10635 1/20 0.37
▸ CYP2C19 P33261 1/20 0.37
▸ HSP90AA1 P07900 1/20 0.37
▸ ALDH1A1 P00352 2/20 0.37
▸ MTNR1B P49286 1/20 0.36
▸ CSF1R P07333 1/20 0.36
▸ RET P07949 1/20 0.36
▸ KIT P10721 1/20 0.36
▸ PDGFRA P16234 1/20 0.36
▸ FLT1 P17948 1/20 0.36
▸ FLT4 P35916 1/20 0.36
▸ KDR P35968 1/20 0.36
▸ FLT3 P36888 1/20 0.36
▸ MEN1 O00255 2/20 0.35
▸ TAS1R3 Q7RTX0 1/20 0.35
▸ TAS1R1 Q7RTX1 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20596625 1.00 ABL1 (0.37) ABL1KMT2ACYP1A2CYP3A4CYP2D6
SCHEMBL23419543 0.89 LMNA (0.36) KMT2ACYP1A2CYP2C19HSP90AA1ALDH1A1
SCHEMBL20596510 0.86 LMNA (0.36) ABL1KMT2ACYP1A2CYP3A4CYP2C19
SCHEMBL20596513 0.86 CSF1R (0.35) ABL1KMT2ACYP2D6HSP90AA1ALDH1A1
SCHEMBL20595912 0.84 MAP2K4 (0.38) HSP90AA1ALDH1A1LMNASMN1; SMN2
SCHEMBL20596077 0.81 HSP90AA1 (0.39) KMT2ACYP1A2CYP2D6HSP90AA1ALDH1A1
SCHEMBL23419396 0.81 NTRK1 (0.37) ABL1HSP90AA1ALDH1A1TP53MAPT
SCHEMBL20595586 0.81 ABL1 (0.41) ABL1KMT2AKDRMEN1MAPT
SCHEMBL20596538 0.76 LMNA (0.38) KMT2ACYP1A2CYP3A4CYP2C19HSP90AA1
SCHEMBL30145317 0.75 MARS2 (0.44) ALDH1A1MAPTKDM4ESMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11584744-B2 Inhibitors of type 1 methionyl-tRNA synthetase and methods of using them UNIVERSITY OF WASHINGTON (US) 2023-02-21 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11584744-B2 Inhibitors of type 1 methionyl-tRNA synthetase and methods of using them AARS1, EMG1, GARS1 ABL1 1481/4885KMT2A 1475/4885CYP1A2 3877/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback